Related Experiment Video
Updated: Oct 19, 2025
05:58
Retinal Detachment Model in Rodents by Subretinal Injection of Sodium Hyaluronate
Published on: September 11, 2013
21.1K
Late recurrence in birdshot chorioretinopathy
Arash Maleki1, Sydney Look-Why1, Ambika Manhapra1
1Massachusetts Eye Research and Surgery Institution, Waltham, MA; Ocular Immunology and Uveitis Foundation, Waltham, MA.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie
|September 17, 2021
Summary
Birdshot chorioretinopathy (BSCR) patients with late recurrence show no distinct characteristics. A minimum of 30 months of successful treatment is recommended to achieve durable remission and prevent recurrence.
Area of Science:
- Ophthalmology
- Immunology
Background:
- Birdshot chorioretinopathy (BSCR) is a rare inflammatory eye disease.
- Understanding factors predicting recurrence is crucial for patient management.
Purpose of the Study:
- To compare BSCR patients with late recurrence versus those in durable remission.
- To identify predictive characteristics for late recurrence.
Main Methods:
- Retrospective observational case series of 55 BSCR patients.
- Analysis of demographic, clinical, ancillary testing, and multimodal imaging data.
- Receiver operating characteristic (ROC) and Kaplan-Meier survival curve analysis.
Main Results:
- No statistically significant differences in demographic, clinical, or imaging parameters between groups.
- Ideal duration for successful therapy to induce durable remission identified as 30 months (70% sensitivity, 40% specificity).
- Late recurrence observed within 30 months after treatment cessation.
Conclusions:
- Predictive characteristics for late BSCR recurrence are not identifiable.
- A recommended duration of 30 months of successful treatment is suggested to optimize remission.
